Neuronetics, Inc. (NASDAQ:STIM) CFO Sells $71,131.77 in Stock

Neuronetics, Inc. (NASDAQ:STIM) CFO Stephen Furlong sold 17,307 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $4.11, for a total value of $71,131.77. Following the transaction, the chief financial officer now owns 454,420 shares in the company, valued at $1,867,666.20. This trade represents a 3.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Stephen Furlong also recently made the following trade(s):

• On Wednesday, February 12th, Stephen Furlong sold 10,845 shares of Neuronetics stock. The stock was sold at an average price of $3.83, for a total value of $41,536.35.
• On Monday, February 10th, Stephen Furlong sold 14,836 shares of Neuronetics stock. The stock was sold at an average price of $3.28, for a total value of $48,662.08.

Neuronetics Trading Up 7.6 %

STIM stock opened at $4.80 on Friday. Neuronetics, Inc. has a fifty-two week low of $0.52 and a fifty-two week high of $5.07. The business’s 50 day moving average price is $2.48 and its two-hundred day moving average price is $1.50. The company has a current ratio of 3.16, a quick ratio of 2.87 and a debt-to-equity ratio of 4.90.

Institutional Trading of Neuronetics

Hedge funds and other institutional investors have recently made changes to their positions in the stock. HighTower Advisors LLC grew its stake in shares of Neuronetics by 55.5% in the 3rd quarter. HighTower Advisors LLC now owns 245,982 shares of the company’s stock worth $187,000 after buying an additional 87,816 shares during the last quarter. GSA Capital Partners LLP grew its stake in shares of Neuronetics by 64.5% in the 3rd quarter. GSA Capital Partners LLP now owns 78,642 shares of the company’s stock worth $60,000 after buying an additional 30,837 shares during the last quarter. Landscape Capital Management L.L.C. purchased a new stake in shares of Neuronetics in the 3rd quarter worth approximately $53,000. Balyasny Asset Management L.P. grew its stake in shares of Neuronetics by 29.5% in the 4th quarter. Balyasny Asset Management L.P. now owns 1,481,771 shares of the company’s stock worth $2,386,000 after buying an additional 337,539 shares during the last quarter. Finally, JPMorgan Chase & Co. grew its stake in shares of Neuronetics by 10,954.1% in the 4th quarter. JPMorgan Chase & Co. now owns 54,939 shares of the company’s stock worth $88,000 after buying an additional 54,442 shares during the last quarter. Hedge funds and other institutional investors own 53.59% of the company’s stock.

Neuronetics Company Profile

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.